Brussels, Brussels Hoofdstedelijk Gewest, Belgium The venture was found in Europe in Belgium. The main office of represented Corporate Investor is situated in the Brussels.
The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Eurostars, startups are often financed by OCCIDENT, Zu00fcrcher Kantonal Bank, Innovate UK. The meaningful sponsors for the fund in investment in the same round are EASME - EU Executive Agency for SMEs, Walloon, Spinventure. In the next rounds fund is usually obtained by Innovate UK, investiere | Verve Capital Partners, Biomedical Catalyst Fund.
The fund is generally included in 2-6 deals every year. The high activity for fund was in 2019. Deals in the range of 1 - 5 millions dollars are the general things for fund. Considering the real fund results, this Corporate Investor is 66 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Eurostars performs on 24 percentage points less the average number of lead investments.
The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight RetinAI Medical AG, Hylomorph, Smart Reporting. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular fund investment industries, there are Biotechnology, Medical Device.
Related Funds
| Fund Name | Location |
| Achain | Beijing, Beijing, China |
| AKAKIYA HOLDINGS | Japan, Tokyo |
| Alisamiah Investment | - |
| Arba Finance Ltd. | - |
| Broadway Angels | California, San Francisco, United States |
| Collinstar Capital | Australia, Melbourne, Victoria |
| Data Applications | Japan, Tokyo |
| Emerging Innovations Fund | - |
| Fangde Zhilian Investment | China, Guangdong, Shenzhen |
| IDO Investments | Masqat, Muscat, Oman |
| JJ Albanese | California, Santa Clara, United States |
| Morgan Partners | Massachusetts, Newton, United States |
| Pario Ventures | - |
| Raza Foundries | California, San Jose, United States |
| Shanghai Hongyu Asset Management | China, Shanghai |
| Steelhead Ventures, LLC | California, San Francisco, United States |
| WILO | Dortmund, Germany, Nordrhein-Westfalen |
| Yunhao Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
PhysioMRI | $4M | 13 Sep 2023 | France, Idaho, United States | ||
KUORI | $2M | 24 Jan 2023 | Basel, Basel-Stadt, Switzerland | ||
Convert Pharmaceuticals | $16M | 28 Feb 2018 | Liège, Liège, Belgium |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
PhysioMRI | $4M | 13 Sep 2023 | France, Idaho, United States | ||
KUORI | $2M | 24 Jan 2023 | Basel, Basel-Stadt, Switzerland | ||
Convert Pharmaceuticals | $16M | 28 Feb 2018 | Liège, Liège, Belgium |
